ZBIO:NASDAQZenas BioPharma, Inc. Analysis
Data as of 2026-09-01 - not real-time
$32.32
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $32.32, Zenas BioPharma, Inc. shows a bullish moving-average alignment, with shorter averages sitting above longer ones. Over a rolling month the price has gained 5.3%. RSI sits at 54.9, which reads as neutral, and MACD momentum is bearish. Price has been bracketed by support at $27.81 and resistance at $33.99.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 45.4% above where the shares trade now.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 53.7%, a beta of 0.83 and a maximum drawdown of 64.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 45.4% above where the shares trade now.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 53.7%, a beta of 0.83 and a maximum drawdown of 64.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.
Top Market Events
- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27,2027 -Zenas BioPharma Inc. NASDAQ:ZBIO is one of the best IPO stocks with huge upside potential. On June 2, Zenas announced...Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635 C 4 .
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 26.05
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 26.05
- Analyst targets imply +45.4% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Analyst targets imply +45.4% versus the current price
- Negative return on equity of -199.0%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
P/E Ratio-6.9
ROE-199.04%
ROA-34.42%
Debt/Equity120.54
P/B Ratio8.3
Op. Cash Flow$-225972000
Free Cash Flow$-211391632
Industry P/E30.4
Technical Analysis
TrendBullish
RSI54.9
Support$27.81
Resistance$33.99
MA 20$31.73
MA 50$29.72
MA 200$26.05
MACDBearish
VolumeIncreasing
Fear & Greed Index93.23
Valuation
Target Price$47.00
Upside/Downside45.42%
GradeFair
TypeGrowth
Risk Assessment
Beta0.83
Volatility53.65%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.